参芎葡萄糖联合呋塞米对慢性阻塞性肺疾病合并肺源性 心脏病患者h-FABP、NT-proBNP 水平的影响.

OBJECTIVE: To probe into the effects of Shenxiong glucose combined with furosemide on levels of heart type-fatty acid binding protein (h-FABP ) and serum N-terminal B-type pro brain natriuretic peptide (NT-proBNP) in patients with chronic obstructive pulmonary disease (COPD) complicated with cor pulmonale. METHODS: A total of 120 patients with COPD complicated with pulmonary heart disease admitted into Shijiazhuang Hospital of Traditional Chinese Medicine from May 2020 to May 2021 were selected and divided into observation group and control group via the random number table, with 60 cases in each group. The control group was treated with furosemide, while the observation group was given Shenxiong glucose combined with furosemide. The therapeutic effect, the h-FABP and NT-proBNP levels, and the cardio-pulmonary function before and after treatment were compared between two groups, and the incidences of adverse drug reactions of the two groups were observed. RESULTS: The total effective rate of the observation group was 93. 33% (56 / 60), which was significantly higher than that of the control group (80. 00%, 48 / 60), with statistically significant difference (P<0. 05). Compared with before treatment, the h-FABP and NT-proBNP levels of both groups were lower after treatment, and those of the observation group were significantly lower than the control group, with statistically significant differences (P<0. 05). Compared with before treatment, the cardiac output, ejection fraction and stroke volume of both groups were higher after treatment, and those of the observation group were significantly higher than the control group, with statistically significant differences (P<0. 05). Compared with before treatment, the forced vital capacity, forced expiratory volume in 1 s and arterial partial pressure of oxygen of both groups were higher after treatment, and those of the observation group were significantly higher than the control group, with statistically significant differences (P < 0. 05). The incidence of adverse drug reactions of observation group was 6. 67% (4 / 60), which was significantly lower than that of the control group (28. 33%, 17 / 60), with statistically significant difference (P<0. 05). CONCLUSIONS: Shenxiong glucose combined with furosemide in the treatment of patients with COPD complicated with PHD has good curative effect and high safety, which can reduce the h-FABP and NT-proBNP levels, and improve the cardio-pulmonary function. [ABSTRACT FROM AUTHOR]